Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Reiners

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Clinical Endocrinology|December 11, 2008
Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinomaFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSHMichael Lassmann, Heribert Hänscheid, Christoph Reiners, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2014
Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patientsFrederik A Verburg, Uwe Mäder, Christoph Reiners, et al.
Hormones (Athens, Greece)|December 7, 2007
Thyroid cancer in childhood: management strategy, including dosimetry and long-term resultsMarkus Luster, Michael Lassmann, Lutz S Freudenberg, et al.
Clinical Endocrinology|March 25, 2018
The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7Frederik A Verburg, Uwe Mäder, Markus Luster, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 24, 2015
Endogenous TSH levels at the time of <sup>131</sup>I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortalityAlexis Vrachimis, Burkhard Riemann, Uwe Mäder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2015
Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancerFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2008
Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinomaFrederik A Verburg, Markus Dietlein, Michael Lassmann, et al.
Thyroid : Official Journal of the American Thyroid Association|April 19, 2018
Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and <sup>131</sup>I AblationFrederik A Verburg, Uwe Mäder, Luca Giovanella, et al.
Nature Reviews. Endocrinology|August 10, 2011
Radioiodine for remnant ablation and therapy of metastatic diseaseChristoph Reiners, Heribert Hänscheid, Markus Luster, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Clinical Endocrinology|December 11, 2008
Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinomaFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSHMichael Lassmann, Heribert Hänscheid, Christoph Reiners, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2014
Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patientsFrederik A Verburg, Uwe Mäder, Christoph Reiners, et al.
Hormones (Athens, Greece)|December 7, 2007
Thyroid cancer in childhood: management strategy, including dosimetry and long-term resultsMarkus Luster, Michael Lassmann, Lutz S Freudenberg, et al.
Clinical Endocrinology|March 25, 2018
The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7Frederik A Verburg, Uwe Mäder, Markus Luster, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 24, 2015
Endogenous TSH levels at the time of <sup>131</sup>I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortalityAlexis Vrachimis, Burkhard Riemann, Uwe Mäder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2015
Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancerFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2008
Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinomaFrederik A Verburg, Markus Dietlein, Michael Lassmann, et al.
Thyroid : Official Journal of the American Thyroid Association|April 19, 2018
Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and <sup>131</sup>I AblationFrederik A Verburg, Uwe Mäder, Luca Giovanella, et al.
Nature Reviews. Endocrinology|August 10, 2011
Radioiodine for remnant ablation and therapy of metastatic diseaseChristoph Reiners, Heribert Hänscheid, Markus Luster, et al.
Pageof 14